Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

被引：0
|
作者：
Francisco Robert
Alan Sandler
Joan H. Schiller
Glenn Liu
Karen Harper
Lev Verkh
Xin Huang
Jennifer Ilagan
Lesley Tye
Richard Chao
Anne M. Traynor
机构：
[1] University of Alabama at Birmingham,
[2] Comprehensive Cancer Center,undefined
[3] Oregon Health & Science University,undefined
[4] University of Texas Southwestern,undefined
[5] Division of Hematology and Oncology,undefined
[6] University of Wisconsin Carbone Cancer Center,undefined
[7] Pfizer Inc,undefined
[8] Global Research and Development,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Sunitinib; Docetaxel; Solid tumors; Phase I; NSCLC; Antiangiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：669 / 680
页数：11
相关论文
共 50 条
  • [31] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [32] Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
    Saif, Muhammad Wasif
    Sarantopoulos, John
    Patnaik, Amita
    Tolcher, Anthony W.
    Takimoto, Chris
    Beeram, Murali
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1565 - 1573
  • [33] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
    Gordon, Michael S.
    Springett, Gregory M.
    Su, Yungpo Bernard
    Ould-Kaci, Mahmoud
    Wind, Sven
    Zhao, Yihua
    LoRusso, Patricia M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
  • [34] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [35] Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
    F. Caponigro
    D. Lorusso
    G. Fornari
    C. Barone
    M. Merlano
    M. Airoldi
    M. Schena
    R. MacArthur
    S. Weitman
    M. G. Jannuzzo
    S. Crippa
    F. Fiorentini
    A. Petroccione
    S. Comis
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 389 - 394
  • [36] Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
    Caponigro, F.
    Lorusso, D.
    Fornari, G.
    Barone, C.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    MacArthur, R.
    Weitman, S.
    Jannuzzo, M. G.
    Crippa, S.
    Fiorentini, F.
    Petroccione, A.
    Comis, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 389 - 394
  • [37] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
  • [38] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
  • [39] Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
    Muhammad Wasif Saif
    John Sarantopoulos
    Amita Patnaik
    Anthony W. Tolcher
    Chris Takimoto
    Murali Beeram
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1565 - 1573
  • [40] Phase I dose escalation trial of biweekly pemetrexed in combination with docetaxel in advanced solid tumors
    Garland, L. L.
    Cranmer, L., III
    Gerstner, G.
    Walker, R.
    Obregon, Y.
    Ebbinghaus, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345